{"url_path":"/sec/ptix/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-03-09","source_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-009301-index.html","accession_number":"0001493152-26-009301","cik":"0001022899","ticker":"PTIX","issuer_name":"Protagenic Therapeutics, Inc.\\new","edgar_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-009301-index.html","primary_entity_key":"0001022899","primary_entity_name":"Protagenic Therapeutics, Inc.\\new"},"word_count":160,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors**\n\n \n\n*Our\nbusiness is subject to substantial risks and uncertainties. Investing in our securities involves a high degree of risk. You should carefully\nconsider the risk factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC\non March 31, 2025, together with the information contained elsewhere in this report, including Part I, Item 1 “Financial Statements”\nand Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in\nour other SEC filings in evaluating our business. These risks and uncertainties could materially and adversely affect our business, financial\ncondition, results of operations, prospects for growth, and the value of an investment in our securities.*\n\n \n\n*There\nwere no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024,\nfiled with the SEC on March 31, 2025.*"}